Verge and Collaborators Identify Digital Clinical Biomarker Endpoints Sensitive to Short Term Disease Progression in the Pre-treatment Run-in Period of VRG50635 Proof-of-Concept ALS Clinical Trial
Verge Genomics Announces New Development Candidate, VRG201, a Novel Maintenance Therapy for Long-Term Weight Management
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635
Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635
Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics to Present at Mass General Brigham & Bank of America World Medical Innovation Forum
Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical Trial
Verge Genomics to Present at 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023
Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer
VERGE GENOMICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN NOVEMBER
Alice Zhang, CEO & Co-founder of Verge Genomics, Recognized Today by Both Fortune and Fierce Biotech as a Pioneer in AI-Driven Drug Discovery
Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, A Novel Therapeutic for Amyotrophic Lateral Sclerosis
Verge Genomics Appoints John Applegate as Chief Financial Officer
Verge Genomics Honored by Goldman Sachs for Entrepreneurship
